Taxoids Concept

subject area of

• A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer  Academic Article
• A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer  Academic Article
• A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium  Academic Article
• A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial  Academic Article
• A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a  Conference Paper
• A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer  Academic Article
• A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial  Academic Article
• A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients  Academic Article
• A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy  Academic Article
• Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy  Academic Article
• Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins  Academic Article
• Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621  Academic Article
• Amplification of MUC1 in prostate cancer metastasis and CRPC development  Academic Article
• Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel  Academic Article
• Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients  Academic Article
• Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer  Academic Article
• Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial  Academic Article
• Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients  Academic Article
• Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy  Academic Article
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials  Academic Article
• Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial  Academic Article
• Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial  Academic Article
• Dalteparin Low Molecular Weight Heparin (LMWH) in ovarian cancer: A phase II randomized study  Academic Article
• Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study  Academic Article
• Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes  Academic Article
• Effect of docetaxel (taxotere) on expression of radiation-induced lethal mutations in human cell lines  Academic Article
• Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis  Academic Article
• Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials  Academic Article
• Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer  Academic Article
• First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients  Academic Article
• Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy  Academic Article
• Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma  Academic Article
• Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design  Academic Article
• Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect  Academic Article
• Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer  Academic Article
• Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31  Academic Article
• Locally advanced breast cancer in octogenarian women  Academic Article
• Malignant pleural mesothelioma: a phase II trial with docetaxel  Academic Article
• Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer  Academic Article
• Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens  Academic Article
• Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome  Academic Article
• Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial  Academic Article
• Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity  Academic Article
• Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer  Academic Article
• Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy  Academic Article
• Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition  Academic Article
• Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer  Academic Article
• Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer  Academic Article
• Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer  Academic Article
• Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer  Academic Article
• Radiosensitization of Colon Cancer Cell Lines by Docetaxel: Mechanisms of Action  Academic Article
• Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer  Conference Paper
• Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c  Academic Article
• Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer  Academic Article
• Safety of bevacizumab in metastatic breast cancer patients undergoing surgery  Academic Article
• Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America  Academic Article
• Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas  Academic Article
• Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline  Academic Article
• Selection of adjuvant chemotherapy for treatment of node-positive breast cancer  Academic Article
• Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer  Academic Article
• Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy  Academic Article
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.  Academic Article
• Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa  Academic Article
• Symptom clusters using the Brief Pain Inventory in patients with breast cancer  Academic Article
• Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline  Academic Article
• Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review  Academic Article
• TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial  Academic Article
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015  Academic Article
• Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin  Academic Article
• Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study  Academic Article
• Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline  Academic Article
• The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis  Academic Article
• The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Academic Article
• The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.  Academic Article
• Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial  Academic Article
• Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials  Academic Article
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study  Academic Article
• Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421  Academic Article